Colin G. Evans, PhD | Authors

April 19, 2016

Bone metastases in metastatic castration-resistant prostate cancer (mCRPC) can invade a range of sites in the skeleton where they precipitate a spectrum of pathological processes that increase morbidity, negatively affect quality of life, and decrease survival.

January 30, 2016

A recent paper concluded that docetaxel added to standard of care should be considered the new standard of care for men with hormone-sensitive metastatic prostate cancer.

January 27, 2016

The latest results from an open-label, phase Ib study of the STAT3 inhibitor BBI-608 (napabucasin) with a standard chemotherapy (FOLFIRI with or without bevacizumab) in the treatment of advanced colorectal cancer, have been presented at the ASCO 2016 Gastrointestinal Symposium. Evidence of antitumor activity and a favorable safety profile were seen in phase I studies.

January 20, 2016

A team in Australia have revealed the clinicopathological phenotypes and clinical activities of rarer BRAF mutations, namely BRAFK601E (K601E) and BRAFL597 (L597).

January 18, 2016

Building on previous work showing increased NF-kB activity in lung cancers, one research team has recently published a study showing this activity is also enhanced in glioblastoma, one of the most lethal forms of human cancers.

January 18, 2016

A study analysis tackles the ethical debate surrounding the impact of the increasing requirement for research biopsies on the participation of patients with advanced non-small lung cancer in clinical trials.